Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc’h, Darren A.E. Cross, Matthew J. Martin et al.|Molecular Cancer Therapeutics|2018Cited by 113
Modeling of Patient-Derived Xenografts in Colorectal CancerΑναστασία Κατσιαμπούρα, Scott Kopetz, Bradley M. Broom et al.|Molecular Cancer Therapeutics|2017Cited by 66
A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non–Small Cell Lung CancerXing Yi Woo, Carol J. Bult, Anuj Srivastava et al.|Cancer Research|2022Cited by 20
Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.Jonathan W. Riess, Darren A.E. Cross, Nicolas Floc’h et al.|Journal of Clinical Oncology|2017Cited by 8
Patient-derived tumor xenografts in humanized NSG-SGM3 mice: A new immuno-oncology platform.Li‐Chin Yao, James Keck, Jonathan W. Riess et al.|Journal of Clinical Oncology|2016Cited by 4